| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10929 | 2021 |
| Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial G Gravis, K Fizazi, F Joly, S Oudard, F Priou, B Esterni, I Latorzeff, ... The lancet oncology 14 (2), 149-158, 2013 | 908 | 2013 |
| Phyllodes tumor of the breast Y Belkacémi, G Bousquet, H Marsiglia, I Ray-Coquard, N Magné, ... International Journal of Radiation Oncology* Biology* Physics 70 (2), 492-500, 2008 | 328 | 2008 |
| Breaking bad news in oncology: a metasynthesis G Bousquet, M Orri, S Winterman, C Brugière, L Verneuil, A Revah-Levy Journal of Clinical Oncology 33 (22), 2437-2443, 2015 | 212 | 2015 |
| Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO) I Ray-Coquard, A Italiano, E Bompas, A Le Cesne, YM Robin, ... The oncologist 17 (2), 260-266, 2012 | 202 | 2012 |
| Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network G Bousquet, C Confavreux, N Magné, CT de Lara, P Poortmans, ... Radiotherapy and Oncology 85 (3), 355-361, 2007 | 166 | 2007 |
| Targeting cancer stem cells to overcome chemoresistance T Nunes, D Hamdan, C Leboeuf, M El Bouchtaoui, G Gapihan, TT Nguyen, ... International journal of molecular sciences 19 (12), 4036, 2018 | 146 | 2018 |
| 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The Lancet 393 (10191), 2591-2598, 2019 | 139 | 2019 |
| Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model G Gravis, JM Boher, K Fizazi, F Joly, F Priou, P Marino, I Latorzeff, ... European urology 68 (2), 196-204, 2015 | 137 | 2015 |
| Hereditary renal cancer syndromes: an update of a systematic review J Verine, A Pluvinage, G Bousquet, J Lehmann-Che, C De Bazelaire, ... European urology 58 (5), 701-710, 2010 | 132 | 2010 |
| Patients’ quality of life during active cancer treatment: a qualitative study J Sibeoni, C Picard, M Orri, M Labey, G Bousquet, L Verneuil, ... BMC cancer 18, 1-8, 2018 | 118 | 2018 |
| TP53 status and response to treatment in breast cancers M Varna, G Bousquet, LF Plassa, P Bertheau, A Janin BioMed Research International 2011 (1), 284584, 2011 | 113 | 2011 |
| In vivo tumor targeting using a novel intestinal pathogen-based delivery approach KP Janssen, D Vignjevic, R Boisgard, T Falguieres, G Bousquet, ... Cancer research 66 (14), 7230-7236, 2006 | 92 | 2006 |
| Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis TO Bui, JP Feugeas, F Pamoukdjian, G Bousquet European urology 81 (4), 349-361, 2022 | 79 | 2022 |
| 18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study L Vercellino, G Bousquet, G Baillet, E Barre, O Mathieu, PA Just, ... Cancer biotherapy & radiopharmaceuticals 24 (1), 137-144, 2009 | 76 | 2009 |
| How to make anticancer drugs cross the blood–brain barrier to treat brain metastases E Angeli, TT Nguyen, A Janin, G Bousquet International journal of molecular sciences 21 (1), 22, 2019 | 75 | 2019 |
| Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15) G Gravis, P Marino, F Joly, S Oudard, F Priou, B Esterni, I Latorzeff, ... European journal of cancer 50 (5), 953-962, 2014 | 74 | 2014 |
| In vivo Distribution of Inorganic Nanoparticles in Preclinical Models M Varna, P Ratajczak, I Ferreira, C Leboeuf, G Bousquet, A Janin Scientific Research Publishing, 2012 | 73 | 2012 |
| Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic … P Lavaud, G Gravis, S Foulon, F Joly, S Oudard, F Priou, I Latorzeff, ... European urology 73 (5), 696-703, 2018 | 66 | 2018 |
| Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells A Ghoul, M Serova, L Astorgues-Xerri, I Bieche, G Bousquet, M Varna, ... Cancer research 69 (10), 4260-4269, 2009 | 66 | 2009 |
